Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.74 |
| ▸ | RAB9A | P51151 | 10/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.58 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | GALR3 | O60755 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4320695 | 0.96 | NPC1 (0.69) | NPC1RAB9AMAPTHCRTR1HCRTR2 | |
| SCHEMBL17102006 | 0.89 | NPC1 (0.59) | NPC1RAB9AMAPTHCRTR1HCRTR2 | |
| SCHEMBL13281549 | 0.88 | RAB9A (0.56) | NPC1RAB9AMAPTTP53GAA | |
| SCHEMBL20767905 | 0.88 | MAPT (0.67) | NPC1RAB9AMAPTTP53GAA | |
| SCHEMBL2591810 | 0.87 | RAB9A (0.74) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL20767913 | 0.87 | TP53 (0.65) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL31349441 | 0.87 | RAB9A (0.55) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL20767943 | 0.86 | MAPT (0.69) | NPC1RAB9AMAPTHCRTR1HCRTR2 | |
| SCHEMBL29858330 | 0.86 | NPC1 (0.62) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL26962611 | 0.86 | NPC1 (0.62) | NPC1RAB9AMAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | Wu, Xiao Hua (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | Wu, Xiao Hua (US) | 2019-03-05 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100144712-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-06-10 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | MAN2A1, MAN1B1, ALG1 | NPC1 1159/4885RAB9A 1295/4885MAPT 3316/4885 |
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | NPC1 1742/4885RAB9A 1784/4885MAPT 4787/4885 |
| US-20100144712-A1 | TRIAZOLE DERIVATIVES HAVING ANTIFUNGAL ACTIVITY, METHOD FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CYP51A1, ERG28, CYP3A7 | NPC1 88/4885RAB9A 2101/4885MAPT 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.